MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
36.55
-0.93
-2.48%
Pre Market: 36.98 +0.43 +1.18% 07:38 05/12 EDT
OPEN
37.48
PREV CLOSE
37.48
HIGH
38.01
LOW
35.60
VOLUME
1
TURNOVER
0
52 WEEK HIGH
57.99
52 WEEK LOW
25.83
MARKET CAP
3.85B
P/E (TTM)
-7.1205
1D
5D
1M
3M
1Y
5Y
1D
Crinetics price target lowered to $84 from $87 at Oppenheimer
TipRanks · 19h ago
Twilio To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 19h ago
Crinetics Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 20h ago
Crinetics Pharmaceuticals Price Target Cut to $84.00/Share From $87.00 by Oppenheimer
Dow Jones · 20h ago
Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $84
Benzinga · 20h ago
CRINETICS PHARMACEUTICALS <CRNX.O>: OPPENHEIMER CUTS TARGET PRICE TO $84 FROM $87
Reuters · 1d ago
Weekly Report: what happened at CRNX last week (0504-0508)?
Weekly Report · 1d ago
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Reuters · 1d ago
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.